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Frailty is increasingly relevant for clinicians to improve care for vulnerable older adults. Prominent frailty measures
include the frailty phenotype and the frailty index. The frailty phenotype is grounded in a theoretical construct
hypothesized to have an underlying biological basis. The frailty index describes frailty as a nonspecific age-associated
vulnerability, reflected in an accumulation of medical, social, and functional deficits. Building on this model, Minitski et al.
describe the development of a biological index that proves to be a reasonable method to predict mortality when
compared to other frailty measurements. Strengths include its ability to import clinical measures, interchangeable
components, and its potential ability to identify latent risk factors. Obstacles include the lack of a unifying biological
theory related to aging, inclusion of costly research measures, and its inability to provide specific clues to the etiology
of frailty according to the frailty index definition. Refinement in measures focused on aging-related biological changes
rather than using measures that result from chronic disease states could help provide important biological insights and
aid in the development of future treatment and preventive modalities.
Please see related article: http://www.biomedcentral.com/1741-7015/13/161.
Keywords: Frailty, Frailty index, Frailty phenotypeFrailty in older adults is most often defined as a late-life
vulnerability to adverse health outcomes [1, 2]. It has
long been an important research topic in geriatric medi-
cine and utilized in research settings to identify at-risk
older adults and to study biological underpinnings that
drive observed vulnerability. It has more recently gained
momentum amongst subspecialists in clinical practice as
a method to identify vulnerable individuals undergoing
medical or surgical interventions [3].
Although frailty consensus work has focused on phys-
ical frailty [1, 2, 4], a theoretically based construct built
around a core group of activity-based and strength-
based measurements, the frailty index (FI), has emerged
as a useful strategy to measure risk for mortality and
other adverse health outcomes in older adults. The FI
utilizes simple counts of up to 71 co-morbidities, labora-
tory measures, and social and functional declines
(termed deficits) to construct a score [5]. Proponents of
this approach have noted that the component measures
are interchangeable, the approach can be applied in bed-
bound or ambulatory populations, and fewer variables* Correspondence: jwalston@jhmi.edu
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stated.can successfully predict mortality than originally pro-
posed [6].
In the present study [7], Mitnitski et al. develop an
aging-related biological index that utilizes 40 biological
measures found to be age-associated in the Newcastle
85+ study. This index contains measures ranging from
telomere length to induced cytokine production from
isolated lymphocytes to the components of a complete
blood count. Although prior studies of older adults have
developed indices focused on clinical laboratory mea-
surements, the authors are to be commended for work-
ing toward the development of an index that attempts to
assess biological age and associated risk through bio-
logical measurements. Their findings regarding the com-
plementarity of clinical and biological measures for
predicting mortality risk are potentially important: One
can imagine, for example, the identification of older
adults who “look” healthy but may benefit from inter-
ventions to address significant latent risk factors. Model-
ing to identify potential modification of risk predicted by
each given FI value by the biological measure value
could further the two measures’ utility.
There are clear strengths to using an index approach
for risk assessment. Any clinical measures included
could be abstracted from medical records with minimalccess This article is distributed under the terms of the Creative Commons
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be for the most part interchanged with other measures
without substantial change in the predictive ability of
the tools [6]. There are likely a large number of age-
related aggregated biological precursors that drive frailty
and late-life decline, and the systemic effects as mea-
sured by risk to adverse outcomes can in part be de-
tected through an index approach. Hence the approach
can be used to predict outcomes, and the combination
of FI and a biomarker-based frailty index (FI-B) seems to
hold considerable promise to this end. The approach
also likely allows the tracking of vulnerability in a rea-
sonable way.
Despite this flexibility in measurement and substantial
predictive ability of a high index score, notable obstacles
remain if this approach is to be further developed as a
true biological aging index or measure of systemic ef-
fects. For example, it is not clear that systemic effects
are being measured unless index components are se-
lected and validated vis a vis a system. Moreover, includ-
ing a preponderance of age-associated clinical measures
may result in an assessment of chronic disease states
rather than aging per se. The FI-B construction, and the
authors’ characterization of frailty as “a state of increased
risk, compared with others of the same age,” suggests
that any marker conferring risk of mortality (or possibly
other adverse geriatric outcomes) contributes usefully to
frailty measurement. We, and others who consider frailty
as a specific physiological state with a definable pheno-
typic presentation, would disagree. The specificity em-
bedded within the phenotype approach offers benefits if
the goal is to elucidate mechanisms and physiological
etiology. To approach such a goal scientifically, theories
describing plausible processes by which frailty arises,
and how they are linked to one another, are needed. In-
dices (psychometrically: as opposed to “scales”) fail to
provide this. Moreover, the more heterogeneously a large
collection of variables arises, the higher the risk of mask-
ing a key driver that can be targeted by specific interven-
tions. In sum, various conceptualizations of frailty have
complementary strengths; however, if etiology is to be
elucidated and targeted interventions are to be pursued,
we believe the field would benefit from more strongly
distinguishing disparate concepts which currently share
the single label of “frailty.”
Regarding risk prediction, the current paper’s ap-
proach has notable strengths but also a feature mandat-
ing caution and further investigation. Among the
strengths, definition of biological “deficits” to maximize
survival discrimination is highly appealing. Moreover,
analysis over random item subsets superbly well eluci-
dates (lack of ) sensitivity of predictive accuracy to the
choice of specific deficits. However it is important to
recognize that the predictive accuracy of the variousindices likely has been overestimated, even for older-old
populations, because analyses appear not to have been
cross-validated (externally or internally, e.g., via a leave-
one-out strategy or use of the bootstrap to estimate bias
rather than variability [8]. The degree of overestimation
could be considerable because of the pre-selection
process to maximize survival discrimination in the ana-
lytic sample. It will be important to see how the mea-
sures perform in external samples, and—as the authors
have noted—to evaluate generalization to outcomes
other than mortality and a broader age range of older
adults.
The FI-B indexing approach as described here could
be refined to include a theoretical construct, and tie the
choice of measures, around aging biology per se [9]. In
addition, to keep the index approach relevant to human
subject translation, focus on pragmatic measurements
that are relatively easily measured in human subjects
must remain a priority in future development rather the
complex and costly research measures included in this
tool. Despite these critiques, the authors are to be
strongly commended for starting a process that could
lead to a better understanding of biological aging and
how it relates, or contributes, to late-life vulnerability.
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